2018
Duvelisib, an oral dual PI3K‐δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study
O'Brien S, Patel M, Kahl BS, Horwitz SM, Foss FM, Porcu P, Jones J, Burger J, Jain N, Allen K, Faia K, Douglas M, Stern HM, Sweeney J, Kelly P, Kelly V, Flinn I. Duvelisib, an oral dual PI3K‐δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study. American Journal Of Hematology 2018, 93: 1318-1326. PMID: 30094870, PMCID: PMC8260004, DOI: 10.1002/ajh.25243.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedFemaleHumansIsoquinolinesLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedNeutropeniaPhosphoinositide-3 Kinase InhibitorsPurinesRemission InductionTransaminasesTreatment OutcomeConceptsChronic lymphocytic leukemiaPhase 1 studyTN patientsRR patientsLymphocytic lymphomaLymphocytic leukemiaRefractory chronic lymphocytic leukemiaMedian response durationAdvanced hematologic malignanciesPhase 3 studyOverall response rateCLL/SLLSmall lymphocytic lymphomaPatient's diarrheaExpansion cohortTransaminase elevationHematologic malignanciesPharmacodynamic activityResponse durationPatientsResponse rateΓ inhibitorDuvelisibDual inhibitorLymphoma
2009
Genetic polymorphisms in the metabolic pathway and non‐Hodgkin lymphoma survival
Han X, Zheng T, Foss FM, Lan Q, Holford TR, Rothman N, Ma S, Zhang Y. Genetic polymorphisms in the metabolic pathway and non‐Hodgkin lymphoma survival. American Journal Of Hematology 2009, 85: 51-56. PMID: 20029944, PMCID: PMC2964927, DOI: 10.1002/ajh.21580.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overArylamine N-AcetyltransferaseConnecticutCytochrome P-450 CYP2E1FemaleFollow-Up StudiesGenotypeGlutathione S-Transferase piGlutathione TransferaseHumansIsoenzymesKaplan-Meier EstimateLeukemia, Lymphocytic, Chronic, B-CellLymphoma, FollicularMiddle AgedPolymorphism, Single NucleotideProportional Hazards ModelsRegistriesYoung AdultConceptsNHL survivalHazard ratioLymphoma survivalChronic lymphocytic leukemia/small lymphocytic lymphomaNon-Hodgkin lymphoma survivalCox proportional hazards modelConnecticut Tumor RegistryKaplan-Meier curvesGenetic polymorphismsSmall lymphocytic lymphomaProportional hazards modelGlutathione S-transferaseCytochrome P450NHL prognosisN-acetyltransferasesTumor RegistryTumor characteristicsIncident casesLymphocytic lymphomaMetabolic pathwaysHazards modelSurvival analysisDrug metabolismEnvironmental carcinogensSurvival
2002
Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox
Gorgun G, Foss F. Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox. Blood 2002, 100: 1399-1403. PMID: 12149223, DOI: 10.1182/blood-2002-01-0300.Peer-Reviewed Original ResearchMeSH KeywordsAdjuvants, ImmunologicAlitretinoinAntineoplastic AgentsB-LymphocytesBexaroteneDiphtheria ToxinGene Expression RegulationHumansInterleukin-2Leukemia-Lymphoma, Adult T-CellLeukemia, Lymphocytic, Chronic, B-CellPrecursor B-Cell Lymphoblastic Leukemia-LymphomaReceptors, Interleukin-2Receptors, Retinoic AcidRecombinant Fusion ProteinsRetinoid X ReceptorsRetinoidsT-LymphocytesTetrahydronaphthalenesTranscription FactorsTretinoinTumor Cells, CulturedConceptsRetinoic acid receptorsImmunomodulatory effectsIL-2RHigh affinity IL-2R expressionCutaneous T-cell lymphomaHigh affinity IL-2R.Interleukin-2 receptor expressionIL-2R expressionT-cell lymphomaB cell leukemia cellsB-cell leukemiaT-cell leukemiaMechanism of actionAutoimmune diseasesHematologic malignanciesClinical activityReceptor expressionLymphoid malignanciesIL-2R.Retinoid X receptor (RXR) familyP75 subunitAcid receptorsRexinoid receptorsLeukemia cellsRexinoids